Welcome to our dedicated page for Stagezero Life news (Ticker: SZLSF), a resource for investors and traders seeking the latest updates and insights on Stagezero Life stock.
StageZero Life Sciences Ltd. (SZLSF) delivers innovative mRNA-based cancer diagnostics and integrated telehealth solutions through its Aristotle test and Care Oncology Clinic. This page provides official press releases and financial updates directly from the company, offering stakeholders timely insights into its advancements in early cancer detection and precision medicine.
Investors and researchers will find curated announcements covering clinical trial milestones, regulatory developments, and strategic partnerships. Key focus areas include updates on the company’s non-invasive liquid biopsy technology, telehealth program expansions, and laboratory accreditations (CAP/CLIA certified).
All content is sourced from verified corporate communications to ensure accuracy. Bookmark this page for streamlined access to StageZero’s latest progress in mRNA diagnostics and oncology care solutions.
StageZero Life Sciences (TSX:SZLS, OTCQB:SZLSF) has applied to extend the expiration of 6,492,420 warrants from January 2023 to January 31, 2024. The warrants were issued through private placements and are not held by company insiders. The extension aims to support shareholders and provide capital of up to C$6.03 million if all warrants are exercised. The company specializes in cancer diagnostics and operates a telehealth program, with its key product, Aristotle®, being the first mRNA multi-cancer panel for early detection.
StageZero Life Sciences (TSX:SZLS, OTCQB:SZLSF) reported its Q3 2022 financial results on November 15, 2022. The company generated $0.8 million in revenue for the quarter, up from $0.7 million in Q3 2021, while net loss improved to $0.05 million compared to $2.2 million in the previous year. Total revenue for the nine months was $3.1 million, down from $3.6 million year-over-year. Notably, StageZero is transitioning to focus on cancer screening and has initiated partnerships with large employers for its Aristotle cancer detection program.
StageZero Life Sciences will release its third-quarter operational and financial results on November 15, 2022, before markets open. The Chairman and CEO, James Howard-Tripp, will host a conference call at 8:30 a.m. EDT to discuss the results and business developments. Their flagship product, Aristotle, is a pioneering mRNA multi-cancer panel tested on over 9,000 patients. StageZero Life Sciences trades under the symbol SZLSF on the OTCQB.
StageZero Life Sciences announced the closure of a private placement on August 18, 2022, totaling $177,000. Each unit consists of an $1,000 unsecured convertible debenture, yielding 8% interest over 18 months, convertible at $0.11 per share, and 9090 common share purchase warrants exercisable at CAD$0.15 for 18 months. Proceeds will support the company's global growth strategy and the commercialization of its products including Aristotle. CEO James Howard-Tripp emphasized a flexible financing strategy to manage cash flow and minimize shareholder dilution.
FAQ
What is the current stock price of Stagezero Life (SZLSF)?
What is the market cap of Stagezero Life (SZLSF)?
